These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32648337)
1. Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer. Ke FY; Chen WY; Lin MC; Hwang YC; Kuo KT; Wu HC Cancer Sci; 2020 Oct; 111(10):3478-3492. PubMed ID: 32648337 [TBL] [Abstract][Full Text] [Related]
2. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Ahmed N; Riley C; Rice G; Quinn M Clin Exp Metastasis; 2005; 22(5):391-402. PubMed ID: 16283482 [TBL] [Abstract][Full Text] [Related]
3. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Gourley C; Paige AJ; Taylor KJ; Ward C; Kuske B; Zhang J; Sun M; Janczar S; Harrison DJ; Muir M; Smyth JF; Gabra H Cancer Res; 2009 Jun; 69(11):4835-42. PubMed ID: 19458077 [TBL] [Abstract][Full Text] [Related]
4. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872 [TBL] [Abstract][Full Text] [Related]
6. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts. Becker MA; Haluska P; Bale LK; Oxvig C; Conover CA Mol Cancer Ther; 2015 Apr; 14(4):973-81. PubMed ID: 25695953 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer. Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596 [TBL] [Abstract][Full Text] [Related]
8. [Effects of WWOX on ovarian cancer cell attachment in vitro]. Zhang JQ; Li L; Song HL; Adam P; Hani G Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):414-7. PubMed ID: 19950548 [TBL] [Abstract][Full Text] [Related]
9. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289 [TBL] [Abstract][Full Text] [Related]
10. Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer. Arias-Pinilla GA; Dalgleish AG; Mudan S; Bagwan I; Walker AJ; Modjtahedi H Sci Rep; 2020 Jan; 10(1):537. PubMed ID: 31953437 [TBL] [Abstract][Full Text] [Related]
11. p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Geisler HE; Geisler JP; Miller GA; Geisler MJ; Wiemann MC; Zhou Z; Crabtree W Cancer; 2001 Aug; 92(4):781-6. PubMed ID: 11550148 [TBL] [Abstract][Full Text] [Related]
12. Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro. Uruski P; Sepetowska A; Konieczna C; Pakuła M; Wyrwa M; Tussupkaliyev A; Tykarski A; Mikuła-Pietrasik J; Książek K Cell Mol Biol Lett; 2021 Oct; 26(1):44. PubMed ID: 34674640 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. Alper O ; Bergmann-Leitner ES; Bennett TA; Hacker NF; Stromberg K; Stetler-Stevenson WG J Natl Cancer Inst; 2001 Sep; 93(18):1375-84. PubMed ID: 11562388 [TBL] [Abstract][Full Text] [Related]
14. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537 [TBL] [Abstract][Full Text] [Related]
16. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer. Skirnisdottir I; Seidal T Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584 [TBL] [Abstract][Full Text] [Related]
17. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Guo Y; Nemeth J; O'Brien C; Susa M; Liu X; Zhang Z; Choy E; Mankin H; Hornicek F; Duan Z Clin Cancer Res; 2010 Dec; 16(23):5759-69. PubMed ID: 20699329 [TBL] [Abstract][Full Text] [Related]
18. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Yang H; Shu Z; Jiang Y; Mao W; Pang L; Redwood A; Jeter-Jones SL; Jennings NB; Ornelas A; Zhou J; Rodriguez-Aguayo C; Bartholomeusz G; Iles LR; Zacharias NM; Millward SW; Lopez-Berestein G; Le XF; Ahmed AA; Piwnica-Worms H; Sood AK; Bast RC; Lu Z Clin Cancer Res; 2019 Sep; 25(18):5702-5716. PubMed ID: 31391192 [TBL] [Abstract][Full Text] [Related]
19. Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02". Aina OH; Marik J; Gandour-Edwards R; Lam KS Mol Imaging; 2005; 4(4):439-47. PubMed ID: 16285906 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody against human ovarian tumor-associated antigens. Poels LG; Peters D; van Megen Y; Vooijs GP; Verheyen RN; Willemen A; van Niekerk CC; Jap PH; Mungyer G; Kenemans P J Natl Cancer Inst; 1986 May; 76(5):781-91. PubMed ID: 3517452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]